Grifols A : In talks to dispose of stake in Shanghai RAAS
>Grifols notifies Shanghai Raas their intention to dispose of their stake - Grifols has sent a notice to Shanghai RAAS informing them that they are planning to dispose of their stake. The deal is still in the planning stage, so the company has shared only very limited information. If the deal is successfully closed, Grifols expects to receive $ 1.5bn while remaining as a significant shareholder of Shanghai RAAS (their 26.2% stake has a market value of $ 1.74bn). Grifo...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.